3.21
전일 마감가:
$3.12
열려 있는:
$3.12
하루 거래량:
445.10K
Relative Volume:
0.69
시가총액:
$736.26M
수익:
$596.48M
순이익/손실:
$123.72M
주가수익비율:
5.8534
EPS:
0.5484
순현금흐름:
$106.59M
1주 성능:
-1.83%
1개월 성능:
+11.07%
6개월 성능:
+15.88%
1년 성능:
+31.56%
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CVAC
Curevac N V
|
3.21 | 736.26M | 596.48M | 123.72M | 106.59M | 0.5484 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
큐어백 Stock (CVAC) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2023-06-08 | 개시 | SVB Securities | Outperform |
2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
2021-10-22 | 개시 | Deutsche Bank | Hold |
2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
2021-04-26 | 재개 | Credit Suisse | Underperform |
2021-04-26 | 개시 | Guggenheim | Neutral |
2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
2020-09-08 | 개시 | BofA Securities | Buy |
2020-09-08 | 개시 | Credit Suisse | Neutral |
2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance
CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey
CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
CureVac: 2025 will be less costly - marketscreener.com
CureVac Announces Financial Results for the Fourth Quarter and F - GuruFocus
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - Yahoo Finance
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience By GuruFocus - Investing.com Canada
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus
CureVac Reports Strong 2024 Financial Results and Strategic Progress - TipRanks
CureVac Reports 2024 Financial Results and Strategic Advances - TipRanks
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - ACCESS Newswire
CureVac Q4 2024 Earnings Call Transcript - MarketBeat
Insights Ahead: CureVac's Quarterly Earnings - Benzinga
CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN
FDA clears CureVac’s IND application for Phase I lung cancer trial - MSN
FDA clears Curevac’s IND for CVHNLC - BioWorld MedTech
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - sharewise.com
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - ACCESS Newswire
CureVac Financial Results: Key mRNA Biotech Player to Reveal 2024 Performance - Stock Titan
CureVac’s lung cancer therapy clears FDA hurdle - Investing.com Australia
CureVac’s lung cancer therapy clears FDA hurdle By Investing.com - Investing.com South Africa
CureVac's Early-stage Trial of Lung Cancer Drug Gets US FDA Clearance - MarketScreener
CureVac to initiate Phase 1 trial for its lung cancer therapy (CVAC:NASDAQ) - Seeking Alpha
CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy - MarketScreener
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - sharewise.com
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - ACCESS Newswire
CureVac N.V.'s (NASDAQ:CVAC) Profit Outlook - simplywall.st
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares - ACCESS Newswire
Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds? - Yahoo Finance
CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV - ACCESS Newswire
CureVac (NASDAQ:CVAC) Stock Price Down 7.2%What's Next? - MarketBeat
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions (NASDAQ:CVAC) - Seeking Alpha
CureVac (CVAC) Stock Surges After Favorable Patent Ruling - Stocks Telegraph
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga
Lululemon, General Motors and Apple fall premarket; CureVac gains By Investing.com - Investing.com Canada
Lululemon, General Motors and Apple fall premarket; CureVac gains - Investing.com India
CureVac, gold miners, Rocket Lab - TradingView
CureVac Patent Validated in BioNTech Dispute, Infringement Hearing Set for July - Marketscreener.com
PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News - RTTNews
CureVac’s amended patent upheld by European Patent Office By Investing.com - Investing.com South Africa
European Patent Office declares CureVac mRNA patent valid - Marketscreener.com
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):